Suppr超能文献

COVID-19 疫苗接种后甲状腺功能障碍迟发的模式和结局:75 例报告。

Patterns and outcomes of late onset thyroid disturbances after COVID-19 vaccination: A report of 75 cases.

机构信息

Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.

Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.

出版信息

Trop Med Int Health. 2024 Jan;29(1):63-71. doi: 10.1111/tmi.13947. Epub 2023 Nov 20.

Abstract

Isolated cases of subacute thyroiditis exist in the early period of COVID-19 vaccination, largely after mRNA vaccines. Here we report late onset thyroid disturbances and persistent health issues in patients of thyroid disorders after COVID-19 vaccination. Seventy-five patients with post COVID-19 vaccination thyroid disturbances were identified. Among these, 41 had flare of underlying thyroid illness, majority occurring at a median time lag of 28.4 weeks since 2nd dose. Thirty-one cases of new onset hypothyroidism and three of new onset hyperthyroidism were reported, with a median time lag respectively of 17.2 and 22.6 weeks since 2nd dose. Most cases occurred after ChAdOx1-nCoV-19, which was the commonest vaccine employed in mass roll out in India. Significant improvement was observed in majority, after a median follow up of 22-26 weeks. New onset health issues persisting for ≥4 weeks were reported in 37.3% and were common in individuals with history of COVID-19 before vaccine. New onset metabolic, musculoskeletal, and reproductive disorders were the common health complaints. Active monitoring is warranted for late onset adverse events after COVID-19 vaccines of all types. Larger studies with involvement of unvaccinated individuals are required to understand the incidence and causality of late onset thyroid disturbances after COVID-19 vaccines.

摘要

在 COVID-19 疫苗接种的早期,有孤立的亚急性甲状腺炎病例,主要发生在 mRNA 疫苗之后。在这里,我们报告 COVID-19 疫苗接种后甲状腺功能障碍患者的迟发性甲状腺紊乱和持续的健康问题。我们发现了 75 例接种 COVID-19 疫苗后甲状腺功能紊乱的患者。其中,41 例为潜在甲状腺疾病的发作,大多数发生在第二剂后中位数 28.4 周的时间滞后。报告了 31 例新发甲状腺功能减退症和 3 例新发甲状腺功能亢进症,第二剂后中位数时间滞后分别为 17.2 和 22.6 周。大多数病例发生在 ChAdOx1-nCoV-19 之后,这是印度大规模推广中最常用的疫苗。在中位数随访 22-26 周后,大多数病例观察到显著改善。37.3%的患者报告了持续≥4 周的新发健康问题,这些患者在疫苗接种前有 COVID-19 病史。新发的代谢、肌肉骨骼和生殖系统疾病是常见的健康问题。需要对所有类型的 COVID-19 疫苗进行主动监测,以了解迟发性不良事件的发生情况。需要更大规模的研究,包括未接种疫苗的个体,以了解 COVID-19 疫苗接种后迟发性甲状腺功能障碍的发生率和因果关系。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验